USA | Spain | |||
---|---|---|---|---|
Men (N=61) | Women (N=31) | Men (N=61) | Women (N=30) | |
Age, years | 41.5 (31.7–56.9) | 36.2 (31.7–56.8) | 52.0 (46.0–65.4) | 54.6 (43.3–61.4) |
Education, years | 16 (12–17) | 16 (11–18) | 9 (8–12) | 8 (8–12) |
White | 31 (51%) | 17 (55%) | 56 (92%) | 30 (100%) |
Duration disease, years | 12.1 (6.1–21.5) | 6.3 (4–16.6) | 22 (12.1–34.8) | 21.4 (12.1–30.1) |
HLA-B27+ | 26 (68%) | 21 (88%) | 49 (86%) | 20 (69%) |
MDHAQ | ||||
Function, (0–10) | 2 (0.3–4) | 2.3 (0.3–4) | 1.2 (0–2.7) | 0.8 (0–2.3) |
Pain, (0–10) | 4 (1–7) | 5 (2–7.5) | 3 (1.5–6) | 4 (1–5) |
PATGL, (0–10) | 3 (1.5–6.3) | 5 (2–6.5) | 4 (2–5.5) | 3.5 (1–5.5) |
RAPID3, (0–30) | 8.5 (4.2–15.3) | 11.8 (4–16.8) | 6.8 (3.5–14.2) | 8.1 (3.3–12.7) |
Fatigue, (0–10) | 3 (0–6.5) | 5 (3–8) | 3 (1–4.5) | 2.8 (1–5.5) |
Treatment | ||||
Anti-TNFα | 49 (80%) | 22 (71%) | 50 (82%) | 18 (60%)* |
DMARD | 9 (15%) | 7 (23%) | 13 (21%) | 7 (23%) |